Analyst Reco. Bioventus Inc.

Equities

BVS

US09075A1088

Market Closed - Nasdaq Other stock markets 21:00:00 02/05/2024 BST			5-day change	1st Jan Change
3.96 ^USD	-0.75%		-2.70%	-24.86%

03-13	Craig-Hallum Adjusts Price Target on Bioventus to $9 From $6, Maintains Buy Rating	MT
03-12	Transcript : Bioventus Inc., Q4 2023 Earnings Call, Mar 12, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Craig-Hallum Adjusts Price Target on Bioventus to $9 From $6, Maintains Buy Rating	03-13	MT
Canaccord Genuity Upgrades Bioventus to Buy From Hold, Adjusts Price Target to $7 From $3.66	12-07	MT
Craig-Hallum Adjusts Price Target on Bioventus to $5 From $10, Maintains Hold Rating	03/04/23	MT
Goldman Sachs Cuts Price Target on Bioventus to $2.50 From $13, Maintains Neutral Rating	30/11/22	MT
Craig-Hallum Downgrades Bioventus to Hold From Buy	22/11/22	MT
Morgan Stanley Adjusts Price Target on Bioventus to $5 From $11, Maintains Overweight Rating	10/11/22	MT
Canaccord Genuity Downgrades Bioventus to Hold From Buy, Adjusts Price Target to $6 From $18	09/11/22	MT
JPMorgan Downgrades Bioventus to Underweight From Overweight	09/11/22	MT
Morgan Stanley Adjusts Bioventus' Price Target to $11 From $12, Reiterates Overweight Rating	11/10/22	MT
Goldman Sachs Adjusts Bioventus' Price Target to $13 from $15, Maintains Neutral Rating	07/09/22	MT
Morgan Stanley Raises Bioventus' Price Target to $12 From $11, Maintains Overweight Rating	12/08/22	MT
Morgan Stanley Lowers Bioventus Price Target to $11 From $18, Maintains Overweight Rating	12/05/22	MT
Goldman Sachs Adjusts Bioventus Price Target to $17 From $19, Maintains Neutral Rating	21/03/22	MT
Craig-Hallum Starts Bioventus at Buy with $30 Price Target	15/03/22	MT
Morgan Stanley Resumes Bioventus at Overweight With $20 Price Target	15/11/21	MT
JPMorgan Reinstates Bioventus at Overweight With $25 Price Target	10/11/21	MT
BIOVENTUS : Goldman Sachs Cuts Bioventus to Neutral From Buy, Price Target to $19 From $20	01/07/21	MT
BIOVENTUS : Morgan Stanley Adjusts Price Target on Bioventus to $19 From $18, Maintains Overweight Rating	19/04/21	MT
BIOVENTUS : Morgan Stanley Starts Bioventus at Overweight With $18 Price Target	08/03/21	MT
BIOVENTUS : JPMorgan Initiates Bioventus at Overweight With $17 Price Target	08/03/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Bioventus Inc.

Equities

BVS

US09075A1088

Analyst Reco.

Filters